A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
The main purpose of this study is to determine safety and efficacy of orforglipron compared with placebo in adult participants with type 2 diabetes and inadequate glycemic control with diet and exercise alone. The study will last approximately 54 weeks.
Inclusion Criteria:
Exclusion Criteria:
Pittsburgh, Pennsylvania 15243, United States
Kolkata, West Bengal 700020, India
Yamato-shi, Kanagawa 242-0004, Japan
Suita-shi, Osaka 565-0853, Japan
Chuo-ku, Tokyo 103-0002, Japan
Chuo-ku, Tokyo 103-0027, Japan
Chuo-ku, Tokyo 104-0031, Japan
Shinjuku-ku, Tokyo 160-0008, Japan
Chihuahua City, 31110, Mexico